RT Journal Article
SR Electronic
T1 Complementary value of molecular, phenotypic and functional aging biomarkers in dementia prediction
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.23.24309078
DO 10.1101/2024.06.23.24309078
A1 Engvig, Andreas
A1 Kalleberg, Karl Trygve
A1 Westlye, Lars T.
A1 Leonardsen, Esten Høyland
A1 ,
YR 2024
UL http://medrxiv.org/content/early/2024/06/24/2024.06.23.24309078.abstract
AB DNA methylation age (MA), brain age (BA), and frailty index (FI) are putative aging biomarkers linked to dementia risk. We investigated their relationship and combined potential for prediction of stages of cognitive impairment and future risk of dementia using the ADNI database. Of several MA algorithms, DunedinPACE had the strongest association with neuropsychological tests and was included alongside BA and FI in predictive analyses.The pairwise correlations between age- and sex-adjusted measures for MA (aDundedinPACE), brain age (aBA), and frailty (aFI) were low (all <0.15). In a prediction model including age, sex, and aFI, we achieved an area under the curve (AUC) of 0.95 for differentiating cognitively normal controls (CN) from dementia patients in a held-out test set. The best models for CN vs. mild cognitive impairment (MCI) and MCI vs. dementia contained age, sex, aFI and aBA as predictors, and achieved out-of-sample AUCs of 0.82 and 0.83 respectively. When combined with clinical biomarkers (apolipoprotein E ε4 allele count, memory, executive function), a model including aBA and aFI predicted 5-year dementia risk among MCI patients with an out-of-sample AUC of 0.83. aDunedinPACE did not improve the predictions. FI had a stronger adverse effect on prognosis in males, while BA’s impact was greater in females.Our findings highlight complementary value of BA and FI in dementia prediction. The results support a multidimensional view of dementia, including an intertwined relationship between the biomarkers, sex, and prognosis. The tested MA’s limited contribution suggests caution in their use for individual risk assessment of dementia.Competing Interest StatementEsten H. Leonardsen has received honorarium for lecturing from Lundbeck AS. Karl T. Kalleberg is a shareholder of Age Labs, a company focused on developing biomarkers for age-related diseases.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study uses data that are openly available at adni.loni.usc.edu. The present research study was done in accordance with the ADNI data use agreement. Ethics committee/IRB of South-East Norway (REK) gave ethical approval (REK 2018/1127).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData are available at ADNI website. Code will be shared upon request.